Ramipril dosing schedules compared in kidney disease with heart failure
Compares ramipril dosing schedules in chronic kidney disease with heart failure.
Plain-language title generated from the registry record
Registry title: Single and Twice-daily Dosing of Ramipril on Renal Function in Chronic Kidney Disease Patients With Reduced Ejection Fraction Heart Failure
Key facts
- Where
- Kartasura, IndonesiaSee the site
- Phase
- Phase 4
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with chronic kidney disease (stage 3-5, not on dialysis) and heart failure with a low ejection fraction. It compares ramipril taken once a day with ramipril taken twice a day.
- Age
- Older than 18 years
- Sex
- Women and men can join.
- Disease stage
- Chronic kidney disease stage 3-5 without dialysis, and heart failure with ejection fraction below 40%.
- Earlier treatment
- People receiving sacubitril-valsartan or ARB therapy cannot join. People with a history of intolerance or angioedema to ACE inhibitors cannot join.
- Biomarker or test result
- Ejection fraction below 40%.
Main reasons for not taking part
- Receiving hemodialysis
- History of intolerance or angioedema to ACE inhibitors
- Refractory hyperkalemia
- Pregnancy
- Blood pressure below 90/60, or shock
Read by machine on 9 November 2026.
Where in Indonesia
- UNS HospitalKartasura, IndonesiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Evi Liliek Wulandari
- Trial code
- NCT07259512
- Record updated
- 10 December 2025
- Original description
This study compares the effects of once-daily versus twice-daily ramipril dosing on renal function in chronic kidney disease (CKD) patients with heart failure with reduced ejection fraction (HFrEF). Outcomes include changes in plasma renin activity, malondialdehyde, interleukin-6, albuminuria, and cystatin C after 30 days of therapy.Read full original descriptionShow less
Comparative Effects of Single Versus Twice-Daily Ramipril Dosing on Renal Function in Patients With Chronic Kidney Disease and Heart Failure With Reduced Ejection Fraction: Evaluation of Plasma Renin Activity, Malondialdehyde, Interleukin-6, Albuminuria, and Cystatin C
This study compares the effects of once-daily versus twice-daily ramipril dosing on renal function in chronic kidney disease (CKD) patients with heart failure with reduced ejection fraction (HFrEF). Outcomes include changes in plasma renin activity, malondialdehyde, interleukin-6, albuminuria, and cystatin C after 30 days of therapy.
Inclusion: Female or Male with age >18 years old; Patients with a diagnosis of CKD stage 3-5 non-dialysis with low ejection fraction heart failure (ejection fraction < 40%).
Exclusion: Receiving hemodialysis therapy; Receiving sacubitril-valsartan therapy; Receiving ARB therapy; History of intolerance to ACE inhibitors; History of angioedema to ACE inhibitors; Refractory hyperkalemia; Pregnancy; Hypotension with blood pressure <90/60, or patients in shock.